A 66-year-old pre-diseased (CVD, s/p esophagogastric junctional adenocarcinoma) male patient presented with stage IV A ALK-negative, CD30-positive ALCL with lymph node, cutaneous, and pulmonary manifestations, and treatment was initiated with BV-CHP. This evidence concerns the gene ALK and gastroesophageal junction adenocarcinoma.